Indiana University Researcher Receives $1.6 Million NCI Grant for Multiple Myeloma
G. David Roodman, MD, PhD
G. David Roodman, MD, PhD, of Indiana University (IU) Melvin and Bren Simon Comprehensive Cancer Center, has been awarded a 5-year, $1.6 million grant from the National Cancer Institute (NCI) to study ways to build bone and decrease tumor growth in multiple myeloma bone disease. Dr. Roodman is Professor at IU School of Medicine. He is leading the research to investigate a molecule developed with collaborators at the University of Pittsburgh that could repair bone, decrease tumors, and improve outcomes for patients with multiple myeloma on specific targeted therapies.
“We’ve been very interested in understanding the mechanisms underlying the horrific bone disease associated with multiple myeloma, which occurs in up to about 85% of patients and causes devastating pathologic fractures, bone pain, and impacts survival,” Dr. Roodman said in a statement.
Previously, Dr. Roodman and colleagues had shown the importance of the marrow microenvironment on the growth of the tumor cells in the bone destructive process. They, with collaborators at the University of Pittsburgh, developed a small molecule called XRK3F2 to target that bone disease. Animal models and preclinical tissue models have shown the molecule could have an important role also in stopping drug resistance in myeloma cells.
“This grant allows us to look at using a small molecule to show how we can overcome resistance to some of the most potent drugs in use for myeloma,” Dr. Roodman said. “Many patients develop drug resistance over time, and it becomes very difficult to treat them.”
Among newer treatments developed for multiple myeloma are targeted therapies, including the proteasome inhibitors bortezomib and carfilzomib. In models developed by Dr. Roodman’s research team, the XRK3F2 molecule enhanced the effects of these drugs in preclinical models of multiple myeloma.
The molecule also caused new bone formation in animal models, which could lead to treatments for healing bone lesions.
Dr. Roodman and his team will further explore the XRK3F2 molecule to understand the mechanism responsible for its effects on multiple myeloma cells and its potential for new therapies.